GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment opportunities.
With Denmark’s Novo Nordisk (NOV: N) struggling to maintain supplies of its Wegovy (semaglutide), and rival Eli Lilly (NYSE: LLY) now offering its Mounjaro (tirzepatide) for obesity too under the trade name Zepbound, the level of demand is clear, but some are concerned that access may be limited.
In a statement, the American Medical Association (AMA) said insurance coverage barriers could prevent broad accessibility of these treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze